ALKS stock news today

RBC Says Alkermes Lybalvi Exclusivity Extension Offsets Alixorexton Pricing Change

RBC notes that a longer exclusivity period for Alkermes' Lybalvi balances out a pricing adjustment for Alixorexton. The analyst view weighs the two developments against each other.

RBC nudges Alkermes target up to $57

RBC moved its valuation level for Alkermes higher, from $56 to $57. The adjustment reflects a slightly changed view of the drugmaker's shares.

RBC Capital keeps Outperform on Alkermes, lifts target to $57

RBC Capital reiterated its Outperform rating on Alkermes and raised its price target to $57. The change reflects the firm's updated view on the stock.

Wells Fargo keeps Overweight on Alkermes, lifts target to $68

Wells Fargo stayed Overweight on Alkermes and raised its price target to $68. The update reflects the firm's view on the stock.

HC Wainwright keeps Neutral rating on Alkermes, lifts price target to $50

HC Wainwright & Co. maintained a Neutral rating on Alkermes while raising its price target to $50. The change reflects the firm's updated view on the stock.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

Alkermes holds Q3 2026 earnings call

Alkermes discussed its third-quarter 2026 results on an earnings call. The headline gives no figures or details from the call.

Form 8-K tells shareholders about important events such as deals, leadership changes or results.

Alkermes quarterly profit of $0.09 a share tops $(0.06) forecast; revenue $480.100M beats $463.606M view

The drugmaker posted third-quarter results above Wall Street's expectations on both lines. Per-share earnings came in at $0.09 versus a $(0.06) estimate, while revenue of $480.100 million exceeded the $463.606 million projection.

Alkermes begins mid-stage trial of ALKS 7290 in depression

Alkermes has launched a Phase 2 clinical study of its experimental compound ALKS 7290, testing it in people with major depressive disorder. The program now moves into mid-stage human testing.

Alkermes begins Phase 2 trial of ALKS 7290 in major depressive disorder

Alkermes has started a Phase 2 study of ALKS 7290, given alongside antidepressants, in adults with major depressive disorder. The trial moves the drug into mid-stage testing.

Goldman Sachs reinstates Neutral rating on Alkermes with $50 price target

Goldman Sachs resumed coverage of Alkermes with a Neutral rating and set a $50 price target on the stock.

RBC Capital kept its Outperform rating on Alkermes (ALKS).

Baird keeps Outperform rating on Alkermes, lifts target to $61

Baird reiterated its Outperform rating on Alkermes and increased its price target to $61. The move reflects the firm's updated view on the stock.

Alkermes reports experimental drug may offer new approach for ADHD treatment

Alkermes said its experimental drug could provide a new way to treat ADHD. The company did not release specific data or timelines in this announcement.

Needham Reiterates Buy Rating on Alkermes With $62 Price Target

Needham kept its Buy rating on Alkermes and left its $62 price target unchanged. The analyst firm is maintaining its existing view of the stock.

Alkermes reports Phase 1 results for ALKS 7290 in ADHD

Alkermes released topline data from a Phase 1 proof-of-concept trial of ALKS 7290 in patients with attention-deficit hyperactivity disorder. The study showed meaningful improvements in patients.

What is the latest news on ALKS?

Nov 13, 2026: RBC Says Alkermes Lybalvi Exclusivity Extension Offsets Alixorexton Pricing Change (Fiscal.ai) · Nov 4, 2026: RBC nudges Alkermes target up to $57 (Fiscal.ai) · Nov 4, 2026: RBC Capital keeps Outperform on Alkermes, lifts target to $57 (Benzinga)

What are analysts saying about ALKS?

Sep 22, 2026: RBC Capital kept its Outperform rating on Alkermes (ALKS).

What has ALKS filed with the SEC recently?

Nov 3, 2026: Alkermes plc. filed an insider trading report (Form 4) · Nov 3, 2026: Alkermes plc. filed a report on a major company event (Form 8-K)